Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Am Cancer Soc. 2021;71(3):209–49.
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. The global cancer observatory: cancer today. 2020. https://gco.iarc.fr/today/home. Accessed 21 Dec 2022.
Thun MJ, Carter BD, Feskanich D, Freedman ND, Prentice R, Lopez AD, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351–64.
Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. J Thorac Oncol. 2008;3(8):819–31.
Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907.
Oudkerk M, Liu S, Heuvelmans MA, Walter JE, Field JK. Lung cancer LDCT screening and mortality reduction—evidence, pitfalls and future perspectives. Nat Rev Clin Oncol. 2021;18(3):135–51.
Barrett J, Hamilton W. Pathways to the diagnosis of lung cancer in the UK: a cohort study. BMC Fam Pract. 2008;9(1):31.
Corner J, Hopkinson J, Fitzsimmons D, Barclay S, Muers M. Is late diagnosis of lung cancer inevitable? Interview study of patients’ recollections of symptoms before diagnosis. Thorax. 2005;60(4):314–9.
Birt L, Hall N, Emery J, Banks J, Mills K, Johnson M, et al. Responding to symptoms suggestive of lung cancer: a qualitative interview study. BMJ Open Respir Res. 2014;1(1): e000067.
Hamilton W, Peters TJ, Round A, Sharp D. What are the clinical features of lung cancer before the diagnosis is made? A population based case-control study. Thorax. 2005;60(12):1059–65.
Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA. 2012;307(22):2418–29.
Henschke CI, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet (London, England). 1999;354(9173):99–105.
Diederich S, Wormanns D, Semik M, Thomas M, Lenzen H, Roos N, et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers. Radiology. 2002;222(3):773–81.
Pastorino U, Bellomi M, Landoni C, De Fiori E, Arnaldi P, Picchio M, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. The Lancet. 2003;362(9384):593–7.
Walter JE, Heuvelmans MA, Bock GHD, Yousaf-Khan U, Groen HJM, Aalst CMVD, et al. Characteristics of new solid nodules detected in incidence screening rounds of low-dose CT lung cancer screening: the NELSON study. Thorax. 2018;73(8):741–7.
Ostrowski M, Marjański T. Low-dose computed tomography screening reduces lung cancer mortality. Adv Med Sci. 2018;63:230–6.
Quaife SL, Ruparel M, Dickson JL, Beeken RJ, McEwen A, Baldwin DR, et al. Lung Screen uptake trial (LSUT): randomized controlled clinical trial testing targeted invitation materials. Am J Respir Crit Care Med. 2020;201(8):965–75.
Marcus PM, Lenz S, Sammons D, Black W, Garg K. Recruitment methods employed in the National Lung Screening Trial. J Med Screen. 2012;19(2):94–102.
McRonald FE, Yadegarfar G, Baldwin DR, Devaraj A, Brain KE, Eisen T, et al. The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer Prev Res (Phila). 2014;7(3):362–71.
Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.
Aberle DR, Adams AM, Berg CD, Clapp JD, Clingan KL, The National Lung Screening Trial Research Team Writing committee, et al. Baseline characteristics of participants in the randomized national lung screening trial. JNCI. 2010;102(23):1771–9.
Hestbech MS, Siersma V, Dirksen A, Pedersen JH, Brodersen J. Participation bias in a randomised trial of screening for lung cancer. Lung Cancer. 2011;73(3):325–31.
Yousaf-Khan U, Horeweg N, van der Aalst C, Ten Haaf K, Oudkerk M, de Koning H. Baseline characteristics and mortality outcomes of control group participants and eligible non-responders in the NELSON lung cancer screening study. J Thorac Oncol. 2015;10(5):747–53.
Zahnd WE, Eberth JM. Lung cancer screening utilization: a behavioral risk factor surveillance system analysis. Am J Prev Med. 2019;57(2):250–5.
Edinburgh Imaging. LUNGSCOT: University of Edinburgh; 2022. https://www.ed.ac.uk/clinical-sciences/edinburgh-imaging/research/themes-and-topics/body-systems/lungs-respiratory/lung-cancer/lungscot. Accessed 25 May 2022.
Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19–32.
Daudt HM, van Mossel C, Scott SJ. Enhancing the scoping study methodology: a large, inter-professional team’s experience with Arksey and O’Malley’s framework. BMC Med Res Methodol. 2013;13:48.
Levac D, Colquhoun H, O’Brien KK. Scoping studies: advancing the methodology. Implementation science : IS. 2010;5:69.
Tricco AC, Antony J, Zarin W, Strifler L, Ghassemi M, Ivory J, et al. A scoping review of rapid review methods. BMC Med. 2015;13:224.
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–73.
Barnett-Page E, Thomas J. Methods for the synthesis of qualitative research: a critical review. BMC Med Res Methodol. 2009;9:59.
Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol. 2008;8(1):45.
Dixon-Woods M, Cavers D, Agarwal S, Annandale E, Arthur A, Harvey J, et al. Conducting a critical interpretive synthesis of the literature on access to healthcare by vulnerable groups. BMC Med Res Methodol. 2006;6(1):35.
Cavers D, Cunningham-Burley S, Watson E, Banks E, Campbell C. Experience of living with cancer and comorbid illness: protocol for a qualitative systematic review. BMJ Open. 2017;7(5): e013383.
Cavers D, Habets L, Cunningham-Burley S, Watson E, Banks E, Campbell C. Living with and beyond cancer with comorbid illness: a qualitative systematic review and evidence synthesis. J Cancer Surviv. 2019;13(1):148–59.
Ali N, Lifford KJ, Carter B, McRonald F, Yadegarfar G, Baldwin DR, et al. Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. BMJ Open. 2015;5(7): e008254.
Carter-Harris L, Brandzel S, Wernli KJ, Roth JA, Buist DSM. A qualitative study exploring why individuals opt out of lung cancer screening. Fam Pract. 2017;34(2):239–44.
Carter-Harris L, Ceppa DP, Hanna N, Rawl SM. Lung cancer screening: what do long-term smokers know and believe? Health Expect. 2017;20(1):59–68.
Delmerico J, Hyland A, Celestino P, Reid M, Cummings KM. Patient willingness and barriers to receiving a CT scan for lung cancer screening. Lung Cancer. 2014;84(3):307–9.
Draucker CB, Rawl SM, Vode E, Carter-Harris L. Understanding the decision to screen for lung cancer or not: a qualitative analysis. Health Expect. 2019;22(6):1314–21.
Greene PA, Sayre G, Heffner JL, Klein DE, Krebs P, Au DH, et al. Challenges to educating smokers about lung cancer screening: a qualitative study of decision making experiences in primary care. J Cancer Educ. 2019;34(6):1142–9.
Jonnalagadda S, Bergamo C, Lin JJ, Lurslurchachai L, Diefenbach M, Smith C, et al. Beliefs and attitudes about lung cancer screening among smokers. Lung Cancer. 2012;77(3):526–31.
Lowenstein M, Vijayaraghavan M, Burke NJ, Karliner L, Wang S, Peters M, et al. Real-world lung cancer screening decision-making: barriers and facilitators. Lung Cancer. 2019;133:32–7.
Percac-Lima S, Ashburner JM, Atlas SJ, Rigotti NA, Flores EJ, Kuchukhidze S, et al. Barriers to and interest in lung cancer screening among Latino and Non-Latino current and former smokers. J Immigr Minor Health. 2019;21(6):1313–24.
Quaife SL, Marlow LAV, McEwen A, Janes SM, Wardle J. Attitudes towards lung cancer screening in socioeconomically deprived and heavy smoking communities: informing screening communication. Health Expect. 2017;20(4):563–73.
Quaife SL, Vrinten C, Ruparel M, Janes SM, Beeken RJ, Waller J, et al. Smokers’ interest in a lung cancer screening programme: a national survey in England. BMC Cancer. 2018;18(1):1–10.
Raju S, Khawaja A, Han X, Wang X, Mazzone PJ. Lung cancer screening: characteristics of nonparticipants and potential screening barriers. Clin Lung Cancer. 2020;21(5):e329–36.
Raz DJ, Wu G, Nelson RA, Sun V, Wu S, Alem A, et al. Perceptions and utilization of lung cancer screening among smokers enrolled in a tobacco cessation program. Clin Lung Cancer. 2019;20(1):e115–22.
Roth JA, Carter-Harris L, Brandzel S, Buist DSM, Wernli KJ. A qualitative study exploring patient motivations for screening for lung cancer. PLoS ONE [Electronic Resource]. 2018;13(7): e0196758.
Schiffelbein JE, Carluzzo KL, Hasson RM, Alford-Teaster JA, Imset I, Onega T. Barriers, facilitators, and suggested interventions for lung cancer screening among a rural screening-eligible population. J Prim Care Community Health. 2020;11:2150132720930544.
Schnoll RA, Bradley P, Miller SM, Unger M, Babb J, Cornfeld M. Psychological issues related to the use of spiral CT for lung cancer early detection. Lung Cancer. 2003;39(3):315–25.
See K, Manser R, Park ER, Steinfort D, King B, Piccolo F, et al. The impact of perceived risk, screening eligibility and worry on preference for lung cancer screening: a cross-sectional survey. ERJ Open Res. 2020. https://doi.org/10.1183/23120541.00158-2019.
Smits SE, McCutchan GM, Hanson JA, Brain KE. Attitudes towards lung cancer screening in a population sample. Health Expect. 2018;21(6):1150–8.
Stephens SE, Foley KL, Miller D, Bellinger CR. The effects of health disparities on perceptions about lung cancer screening (LCS): survey results of a patient sample. Lung. 2019;197(6):735–40.
Tonge JE, Atack M, Crosbie PA, Barber PV, Booton R, Colligan D. “To know or not to know…?” Push and pull in ever smokers lung screening uptake decision-making intentions. Health Expect. 2019;22(2):162–72.
Simmons VN, Gray JE, Schabath MB, Wilson LE, Quinn GP. High-risk community and primary care providers knowledge about and barriers to low-dose computed topography lung cancer screening. Lung Cancer. 2017;106:42–9.
Leventhal H, Kelly K, Leventhal EA. Population risk, actual risk, perceived risk, and cancer control: a discussion. J Natl Cancer Inst Monogr. 1999;25:81–5.
Cavers D, Calanzani N, Orbell S, Vojt G, Steele RJC, Brownlee L, et al. Development of an evidence-based brief ‘talking’ intervention for non-responders to bowel screening for use in primary care: stakeholder interviews. BMC Fam Pract. 2018;19(1):105.
Hersch J, Jansen J, Barratt A, Irwig L, Houssami N, Howard K, et al. Women’s views on overdiagnosis in breast cancer screening: a qualitative study. BMJ. 2013;346: f158.
Henriksen MJV, Guassora AD, Brodersen J. Preconceptions influence women’s perceptions of information on breast cancer screening: a qualitative study. BMC Res Notes. 2015;8(1):404.
von Wagner C, Good A, Whitaker KL, Wardle J. Psychosocial determinants of socioeconomic inequalities in cancer screening participation: a conceptual framework. Epidemiol Rev. 2011;33:135–47.
Feldstein AC, Perrin N, Rosales AG, Schneider J, Rix MM, Glasgow RE. Patient barriers to mammography identified during a reminder program. J Womens Health (Larchmt). 2011;20(3):421–8.
Reynolds LM, Bissett IP, Consedine NS. Emotional predictors of bowel screening: the avoidance-promoting role of fear, embarrassment, and disgust. BMC Cancer. 2018;18(1):518.
Beeken RJ, Simon AE, von Wagner C, Whitaker KL, Wardle J. Cancer fatalism: deterring early presentation and increasing social inequalities? Cancer Epidemiol Biomark Prev. 2011;20(10):2127–31.
Miles A, Rainbow S, von Wagner C. Cancer fatalism and poor self-rated health mediate the association between socioeconomic status and uptake of colorectal cancer screening in England. Cancer Epidemiol Biomark Prev. 2011;20(10):2132–40.
Davis JL, Bynum SA, Katz RV, Buchanan K, Green BL. Sociodemographic differences in fears and mistrust contributing to unwillingness to participate in cancer screenings. J Health Care Poor Underserved. 2012;23(4 Suppl):67–76.
Cavers D, Nelson M, Rostron J, et al. Optimizing the implementation of lung cancer screening in Scotland: focus group participant perspectives in the LUNGSCOT study. Health Expect. 2022;25(6):3246–58. https://doi.org/10.1111/hex.13632.
Brown LR, Sullivan F, Treweek S, et al. Increasing uptake to a lung cancer screening programme: building with communities through co-design. BMC Public Health. 2022;22:815. https://doi.org/10.1186/s12889-022-12998-0.
Doblytė S. The vicious cycle of distrust: access, quality, and efficiency within a post-communist mental health system. Soc Sci Med. 2022;292: 114573.
Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6(1):42.
Bartlett EC, Kemp SV, Ridge CA, et al. Baseline results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation. Lung Cancer. 2020;148:12–9. https://doi.org/10.1016/j.lungcan.2020.07.027.
Wardle J, Steptoe A. Socioeconomic differences in attitudes and beliefs about healthy lifestyles. J Epidemiol Community Health. 2003;57(6):440–3.
Kaushal A, Hirst Y, Tookey S, Kerrison RS, Marshall S, Prentice A, et al. Use of a GP-endorsed non-participant reminder letter to promote uptake of bowel scope screening: A randomised controlled trial in a hard-to-reach population. Prev Med. 2020;141: 106268.
Hope KA, Moss E, Redman CWE, Sherman SM. Psycho-social influences upon older women’s decision to attend cervical screening: a review of current evidence. Prev Med. 2017;101:60–6.
Cantor SB, Volk RJ, Cass AR, Gilani J, Spann SJ. Psychological benefits of prostate cancer screening: the role of reassurance. Health Expect. 2002;5(2):104–13.
Renzi C, Whitaker KL, Wardle J. Over-reassurance and undersupport after a ‘false alarm’: a systematic review of the impact on subsequent cancer symptom attribution and help seeking. BMJ Open. 2015;5(2): e007002.
Barnett KN, Weller D, Smith S, Orbell S, Vedsted P, Steele RJC, et al. Understanding of a negative bowel screening result and potential impact on future symptom appraisal and help-seeking behaviour: a focus group study. Health Expect. 2017;20(4):584–92.
Brain K, Carter B, Lifford KJ, Burke O, Devaraj A, Baldwin DR, et al. Impact of low-dose CT screening on smoking cessation among high-risk participants in the UK Lung Cancer Screening Trial. Lung Cancer. 2017;72(10):912–8.
Steliga MA, Yang P. Integration of smoking cessation and lung cancer screening. Transl Lung Cancer Res. 2019;8(Suppl 1):S88-s94.
Shelton RC, Lee M. Sustaining evidence-based interventions and policies: recent innovations and future directions in implementation science. Am J Public Health. 2019;109(S2):S132–4.